Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
- PMID: 7585092
- DOI: 10.1038/nm0595-442
Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
Abstract
Psoriasis is a hyperproliferative and inflammatory skin disorder of unknown aetiology. A fusion protein composed of human interleukin-2 and fragments of diphtheria toxin (DAB389IL-2), which selectively blocks the growth of activated lymphocytes but not keratinocytes, was administered systemically to ten patients to gauge the contribution of activated T cells to the disease. Four patients showed striking clinical improvement and four moderate improvement, after two cycle of low dose IL-2-toxin. The reversal of several molecular markers of epidermal dysfunction was associated with a marked reduction in intraepidermal CD3+ and CD8+ T cells, suggesting a primary immunological basis for this widespread disorder.
Similar articles
-
Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes.Dig Dis Sci. 1997 Jul;42(7):1542-8. doi: 10.1023/a:1018891432581. Dig Dis Sci. 1997. PMID: 9246061
-
DAB389IL-2 recombinant fusion toxin effect on lymphocyte- and macrophage-producing cytokine subpopulation cells in experimentally induced demyelinating disease in mice.Immunopharmacol Immunotoxicol. 2017 Dec;39(6):318-329. doi: 10.1080/08923973.2017.1369099. Epub 2017 Sep 20. Immunopharmacol Immunotoxicol. 2017. PMID: 28929835 Free PMC article.
-
Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation.Proc Natl Acad Sci U S A. 1989 Dec;86(23):9485-8. doi: 10.1073/pnas.86.23.9485. Proc Natl Acad Sci U S A. 1989. PMID: 2594781 Free PMC article.
-
Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.Ann N Y Acad Sci. 2001 Sep;941:166-76. doi: 10.1111/j.1749-6632.2001.tb03720.x. Ann N Y Acad Sci. 2001. PMID: 11594570 Review.
-
Interplay between keratinocytes and immune cells--recent insights into psoriasis pathogenesis.Int J Biochem Cell Biol. 2009 May;41(5):963-8. doi: 10.1016/j.biocel.2008.10.022. Epub 2008 Nov 5. Int J Biochem Cell Biol. 2009. PMID: 19027868 Review.
Cited by
-
Immunology: A many layered thing.Nature. 2012 Dec 20;492(7429):S52-4. doi: 10.1038/492S52a. Nature. 2012. PMID: 23254971 No abstract available.
-
IL-23 induces atopic dermatitis-like inflammation instead of psoriasis-like inflammation in CCR2-deficient mice.PLoS One. 2013;8(3):e58196. doi: 10.1371/journal.pone.0058196. Epub 2013 Mar 5. PLoS One. 2013. PMID: 23472158 Free PMC article.
-
Update on psoriasis immunopathogenesis and targeted immunotherapy.Semin Immunopathol. 2016 Jan;38(1):11-27. doi: 10.1007/s00281-015-0539-8. Epub 2015 Nov 16. Semin Immunopathol. 2016. PMID: 26573299 Free PMC article. Review.
-
Biologics for psoriasis: a translational research success story.J Invest Dermatol. 2015 May;135(5):1205-1207. doi: 10.1038/jid.2014.549. J Invest Dermatol. 2015. PMID: 25882456 No abstract available.
-
TCR peptide therapy in human autoimmune diseases.Neurochem Res. 2001 Jun;26(6):713-30. doi: 10.1023/a:1010951706830. Neurochem Res. 2001. PMID: 11519731 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials